Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241386 | 0.89 | CA1 (0.48) | CA1CA2TRPV1MAOBNLRP3 | |
| SCHEMBL6692374 | 0.88 | CA1 (0.45) | CA1CA2TRPV1MEN1CYP1A2 | |
| SCHEMBL7995375 | 0.87 | CA1 (0.59) | CA1CA2MAOBMEN1CYP1A2 | |
| SCHEMBL6691735 | 0.87 | CA1 (0.60) | CA1CA2TRPV1 | |
| SCHEMBL7207001 | 0.87 | CA1 (0.47) | CA1CA2TRPV1MAOBNLRP3 | |
| Ammonia Solution, Strong SCHEMBL6691468 | 0.86 | LMNA (0.50) | CA1CA2PPARAMEN1KMT2A | |
| SCHEMBL5184746 | 0.84 | CA1 (0.70) | CA1CA2TRPV1MEN1KMT2A | |
| SCHEMBL4035951 | 0.83 | CACNA1B (0.59) | MAOBPPARA | |
| SCHEMBL30679029 | 0.82 | HTT (0.49) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12957071 | 0.82 | HTT (0.49) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | 4SC AG (DE) | 2004-01-15 | — | — | US | disclosed |
| WO-2003076388-A2 | BIS-ANILINE DERIVATIVES USEFUL AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009973-A1 | Phenylenediamine derivatives N-substituted with benzyl- or heteroarylmethyl- groups | PAH, PNMT, OPRM1 | CA1 2457/4885CA2 1332/4885TRPV1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.